Podcasts about Sarepta

This week, BioSpace is at 50% power as Heather McKenzie and Jef Akst are off attending this year's BIO Conference in Boston. The half-team discusses this week's biggest news: the death of another patient who took Sarepta's Duchenne muscular dystrophy gene therapy Elevidys. The patient was a non-ambulatory teenager who experienced acute liver failure after receiving the gene therapy, which is the same cause of death for an Elevidys patient reported in March. Sarepta announced that it was halting treatments to non-ambulatory patients and on a media call discussed new steps in its therapeutic protocol for preventing further liver injuries.  Elsewhere, mergers and acquisitions are surging across biopharma. Eli Lilly picked up the gene editing company Verve Therapeutics for $1.3 billion, which helped bolster the gene editing space —particularly after Sarepta's report of the death. Supernus bought Sage Therapeutics for $795 million, five months after Sage rejected a smaller offer from Biogen.  BioNTech also got in on the dealmaking, buying its German rival—scientifically and in the courtroom—CureVac for about $1.25 billion. The deal seemed focused mostly on CureVac's early-stage cancer immunotherapy pipeline, but analysts were otherwise left scratching their heads on what BioNTech was getting for its money.  Last week on The Weekly the team discussed the sudden dismissal of the CDC's entire ACIP committee, and this week we have a new slate of members. The eight people replacing the 17 members that were removed last week include allies of HHS Secretary Robert F. Kennedy Jr., many of whom are vaccine skeptics who seem to share his skeptical view of vaccination in general.  

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Estée Lauder ist makaber. Kering ist happy über Renault-CEO. Börse ist happy über Friedenshoffnung. Einen Crash gab's bei Sarepta. Übernahmen gab's bei Santos & Sage. Roku & Whatsapp mögen Werbung. AMD fliegt & Trump macht goldene Handys. Walmart (WKN: 860853) ist mit einem KGV von 40 teurer als viele Tech-Aktien. Die Analysten empfehlen die Aktie trotzdem zum Kauf. Warum und wenn ja, wie viele? Wir klären auf. Bei der Art Basel wird diese Woche Kunst für zig Millionen verkauft. Die Firma dahinter ist an der Börse und deutlich weniger wert als die dort verkaufte Kunst. Was da los bei MCH (WKN: A0Q16U)? Diesen Podcast vom 17.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Carl Quintanilla, David Faber and Sara Eisen kicked off a new week of trading with stocks rebounding sharply and oil prices giving back some of Friday's huge gains  -- despite the ongoing Israel-Iran conflict. President Trump approved U.S. Steel's deal with Nippon Steel, with terms requiring a "golden share" for the U.S. government. Guggenheim's Tesla analyst joined the program nearly a week after his "sell" rating on the stock.  Also in focus: Trump at the G7 in Canada, Meta's WhatsApp to roll out ads directly on its platform, Sarepta plummets, Roku surges on its partnership with Amazon, Circle up 400% since its early June IPO.   Squawk on the Street Disclaimer

Reports this morning that Iran has signaled it wants to de-escalate hostilities with Israel – and restart talks with the US: Carl Quintanilla, Sara Eisen, and David Faber broke down the latest along with key market implications ahead of another rate decision from the Fed on Wednesday – and as energy prices remain surprisingly steady. Plus: A live read from the ground in Alberta, as the G-7 summit begins in Canada.  Rockefeller International's Ruchir Sharma brought his outlook for equities – fresh off an Op-Ed in the Financial Times arguing to not underestimate the Chinese as trade talks continue… Plus: hear from Former Deputy Secretary of State – and lead negotiator for the nuclear agreement with Iran under the Obama Administration – Wendy Sherman's take on what comes next here. Also in focus: Meta rolls out ads on Whatsapp, boosting shares; Sarepta stock plummets after a 2nd death tied to an experimental gene therapy; an exclusive with the CEO of aerospace maintenance company StandardAero, live from the Paris Air Show; and the rumors around AWS that are boosting AMD shares to fresh highs. Squawk on the Street Disclaimer

The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should drive all stakeholders to come together to figure out how to safely treat patients with this new modality. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the opportunity FDA, companies and patient advocates have to share data and identify a safe path forward for the gene therapy field, both in DMD and beyond.The analysts also review promising early data for amylin agonists to treat obesity from Metsera and Eli Lilly, and discuss the vision for FDA's future laid out by Commissioner Marty Makary and CBER director Vinay Prasad. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656214#biotech #biopharma #pharma #lifescience #obesity #FDA #DMD00:01 - Sponsor Message: ICON Biotech01:19 - Gene Therapy Safety11:55 - Amylin in Obesity18:17 - FDA's FutureTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

This week the BioSpace team was sent into an after-hours scramble by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had fired the remaining members of the CDC's Advisory Committee on Immunization Practices. The secretary argued in an op-ed that accompanied the announcement that the “clean sweep” was necessary to “reestablish public confidence in vaccine science.” The move came amid heightening rhetoric from Kennedy about the safety of vaccines and sparked concerns that the Secretary will replace the committee with people who sympathize with his anti-vaccine positions. On the drug development front, Metsera once again made waves with new data for an amylin drug candidate showing weight loss of 8.4% at just 36 days. The drug could be a major competitor for Novo Nordisk's Cagrisema, which has failed to meet the sky-high expectations of investors despite being the leading amylin candidate in the space. And cell and gene therapy was back in the spotlight last week when the FDA held a round table discussion with industry leaders aimed at eliminating barriers to approval for these complex medicines. This support from the FDA came as Sarepta became the first company to receive a platform technology designation intended to streamline future gene therapy reviews and create predictability for new drug applications created using the same technologies.Over in Biopharm Executive, BioSpace looks at right of first negotiation deals in light of Sanofi's deal to buy Vigil Neuroscience. How often do these agreements turn into M&A? After some analysis, Jefferies found that a ROFN is not a golden ticket to a buyout.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Fired employees from the Department of Health and Human Services are suing Robert F. Kennedy Jr. and Elon Musk, claiming their terminations were based on inaccurate and error-ridden information. The lawsuit alleges that HHS leadership knew the records used to guide layoff decisions were flawed. UniQure's regulatory progress has sparked optimism for Huntington's disease patients, with analysts reacting positively to the company's accelerated approval pathway for a gene therapy submission in 2026. Cullinan has made a back-heavy deal in China worth over $700 million for autoimmune T cell engager technology, while Sarepta has won FDA's platform technology designation for gene therapy development. Rapt is shrinking after discontinuing a drug, agileAD is gearing up to challenge J&J in the multiple myeloma Car-T market, and Lilly has signed a deal for long-acting obesity drugs.

Frå 1. juli tek Misjon Sarepta over Bjorliheimen. Ole Andreas Meling fortel at dei lenge har vore i prat med Sveinung Lianes ved Bjorliheimen. Meling fortel at Misjon Sarepta ynskjer å vidareføre mykje av det som har vore, og ynskjer også å utvikle med nye arrangement. Høyr heile intervjuet med Ole Andrea Meling i Misjon Sarepta om tankane dei har for overtakelsen av Bjorliheimen.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Regeneron has acquired ownership of 23andme for $256 million, promising to comply with consumer privacy policies. Makary's proposed rare disease pathway has sparked hope but raised questions among experts. At the American Society of Gene and Cell Therapy meeting, the first personalized in vivo CRISPR therapy was reported. The FDA has cleared the first Alzheimer's blood test, potentially boosting uptake of Alzheimer's disease therapies. Bio-Rad's new Center for Excellence is redefining antibody discovery with their Pioneer Antibody Discovery Platform. FDA regulations are unlikely to save money for the industry, and Applied Therapeutics' rare disease treatment has failed in late-stage trials. The memory gap in forgotten diseases is making a dangerous comeback, and Novo CEO's sudden exit has raised concerns among analysts.FDA Commissioner Marty Makary's proposal for a 'conditional approval' pathway for rare diseases has sparked hope among biopharma companies, but experts are raising concerns about safety, access, and liability due to a lack of details. The FDA and NIH are accelerating the shift away from animal research, which has raised questions about safety and implementation. Meanwhile, FDA cuts have led to chaos in planning for upcoming advisory committee meetings. The Trump administration's efforts to slash regulations may not necessarily benefit the industry as anticipated. Sarepta is seeking to strengthen its case for Elevidys with data in older kids, while other companies such as Incyte and Lilly are making progress with their drug approvals. Overall, the biopharma industry is facing challenges and uncertainties in navigating the evolving regulatory landscape.

Bom dia! Vamos para mais uma #MensagemDoDiaA Escritura de hoje está em 1 Reis 17:6–7, NVI - "Os corvos lhe traziam pão e carne de manhã e de tarde, e ele bebia água do riacho. Algum tempo depois, o riacho secou-se, por falta de chuva."Não se acomodeImagine a cena: o profeta Elias, isolado no deserto, cercado por silêncio e natureza bruta, está escondido por ordem divina. E mesmo naquele lugar aparentemente árido, Deus cuida dele de maneira extraordinária. Todas as manhãs e todas as tardes, corvos — aves normalmente vistas como impuras — trazem pão e carne. Um riacho tranquilo mata sua sede. É como se o céu inteiro estivesse cooperando para protegê-lo e sustentá-lo.Ali, naquele refúgio improvável, Elias encontra conforto. A rotina se estabelece. A provisão é constante. Talvez, em seu coração, ele tenha pensado: “Não existe lugar melhor. Aqui é onde o favor de Deus me alcançou.”Mas então... o riacho seca. Não foi um erro. Não foi negligência. Foi propósito. Naquele silêncio novo, Elias ouve outra instrução: “Levante-se. Vá até Sarepta. Lá, uma viúva cuidará de você.”Ele poderia ter se apegado ao que funcionou até ali. Poderia ter dito: “Aqui eu fui sustentado. Aqui Deus me falou. Não faz sentido sair.” Mas Elias entendeu — quando a fonte seca, não significa que Deus te abandonou. Significa que Ele está te conduzindo para o próximo capítulo.Em Sarepta, Elias não apenas foi sustentado de forma milagrosa. Mas ele também se tornou canal de milagres. O que parecia um fim... era o início de algo muito maior.Talvez hoje você esteja diante de um "riacho seco". Algo que antes fluía bem — um trabalho, um relacionamento, uma rotina — agora parece ter perdido o brilho, a força, a direção. Não entre em pânico. Pode ser apenas Deus dizendo: “É hora de ir mais longe. Eu preparei algo novo para você.”Não se acomode no conforto antigo. Confie no Deus que vai à sua frente, abrindo caminhos e preparando novos começos.Vamos fazer uma oraçãoPai, obrigado por suprir minhas necessidades e cuidar de mim em cada estação da vida. Obrigado também por me tirar da zona de conforto quando é hora de avançar. Eu confio nos Teus planos e aguardo com fé tudo o que estás preparando para mim. Em nome de Jesus, amém.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 9 May 2025. In this episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HVFSXCWENFCU7FLRVPHK3P4WFU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

compartir lo poco es un acto de Fe

====================================================SUSCRIBETEhttps://www.youtube.com/channel/UCNpffyr-7_zP1x1lS89ByaQ?sub_confirmation=1==================================================== DEVOCIÓN MATUTINA PARA MENORES 2025“PALABRITAS DE CORAZÓN”Narrado por: Tatania DanielaDesde: Juliaca, PerúUna cortesía de DR'Ministries y Canaan Seventh-Day Adventist Church ===================|| www.drministries.org ||===================07 de MayoMamá de fe«Vete a vivir a la aldea de Sarepta, que está cerca de la ciudad de Sidón. Yo le he ordenado a una viuda de allí que te alimente». 1 Reyes 17:9.Era una casa simple en una ciudad pequeña. Allí vivían una mamá y su hijo. Ellos no tenían dinero, ropa bonita ni siquiera mucha comida, pero eran felices y estaban agradecidos.La vida se puso aún más difícil para ellos, y pronto solo quedó lo suficiente para hacer un poco de pan. La mamá no lloró ni se desesperó. Fue a buscar leña para hornear el pan. Era una mujer fuerte, que ya había enfrentado dificultades. Creía en los milagros.Entonces, apareció en su puerta un profeta, un hombre que hablaba acerca de Dios y de la esperanza. El profeta Elías le pidió agua, y ella le convidó rápido. Pero cuando pidió un poco de comida, ella tuvo que explicarle la situación de la familia. No tenía casi nada y usarían lo poco que quedaba de ingredientes para un pan. Todos tenían hambre, pero la mujer tuvo la generosidad de preparar y servir el pan para el profeta. Elías dijo que Dios proveería más comida para ellos.Dios hizo un milagro en esa casa: el aceite y la harina no faltaron en las vasijas; simplemente aparecía más y más, y así ellos no pasaron hambre.Mi oración: Señor, ayúdame a tener acciones generosas para con las personas. 

Bioscience breakthroughs are transforming lives in Central Ohio. From cutting-edge gene therapies to world-first medical devices, the region's life sciences sector is booming—and saving lives. This week's Columbus Metropolitan Club forum brings together scientific leaders and business innovators to explore how research, investment, and clinical development are coming together to power the next generation of healthcare innovation.  Featuring:  Dr. Frank Agbogbo, Vice President of Process Development, Forge Biologics  Dr. Erandi De Silva, Investment Partner, Drive Capital  Dr. Louise Rodino-Klapac, Executive Vice President, Head of R&D, and Chief Scientific Officer, Sarepta  Robin Sears, President and CEO, LENTECHS  The host is Tyler Allchin, Managing Director, Healthcare, JobsOhio This forum was created in partnership with the 2025 COSI Science Festival, and was sponsored by: Armatus Bio, Battelle, Holder Construction, Ohio Life Sciences, The Ohio State University Wexner Medical Center, and Sarepta. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. Our livestream partner was The Columbus Dispatch. This forum was also supported by The Ellis. This forum was recorded before a live audience at The Ellis in Columbus' historic Italian Village on April 30, 2025. 

"E Elias lhe disse: Não temas; vai, faze conforme à tua palavra; porém faze dele primeiro para mim um bolo pequeno, e traze-mo aqui; depois farás para ti e para teu filho."( I Re 17:13) Viuvez é um estado de aparente desconsolo, privação e solidão. O luto para mulheres que não possuíam filhos adultos e perdiam seus maridos em Israel significava falência, mendicância e até a morte. Dificilmente uma mulher enlutada ofereceria algum tipo de provisão ou estaria disposta a doar o pouco que tinha por conta do seu estado. Mas quem retém o pouco administra a escassez, e quem guarda o grão nunca provará das espigas. Independente da abundância ou da restrição, a semente sempre será a moeda de prosperidade do Reino. Quem investe na vida do outro atrai para si tesouros que antes estavam retidos. A semeadura sempre apontará para o muito, e a colheita de “um grão” sempre ensinará que não importa o pouco, o plantio determinará a provisão. Foi assim em Sarepta. Uma viúva possuía apenas um punhado de farinha e um bocado de azeite. Esse seria o seu pão, mas do pão ela fez semente. Cozeu um bolo e independente da sua condição, por oferecer primeiro ao profeta, ela intensificou o poder da sua semente tornando-a primícia. Sempre que eu tenho o direito de comer primeiro do meu fruto, do meu salário, do meu trabalho e eu oferto ao outro, a intensidade dessa semente passa a ter efeito multiplicado. Por isso que Elias libera a benção de uma prosperidade continuada sobre aquela viúva: "Porque assim diz o Senhor Deus de Israel: A farinha da panela não se acabará, e o azeite da botija não faltará até ao dia em que o Senhor dê chuva sobre a terra”. Viuvez, luto, desemprego e restrições são estações ímpares que te conectarão ao " modo multiplicação". Nesses ambientes o que você entrega passa a sobejar. Ainda que a viuvez e o desemprego sejam estações de possíveis privações, suas sementes serão chaves de intensas provisões. Independentemente do que teus olhos veem, creia no princípio do reino, pois aquele que semeia andando e chorando voltará com alegria trazendo na mãos os seus feixes. Cumpra princípios e você viverá as promessas.

Introducción¿Cuántos aquí creen en Dios? y ¿Cuántos le creen a Dios? estas son dos cosas totalmentediferentes el creer y creerle. Creer en Dios casi todo el mundo cree que existe un Dios, pero creerlea Dios en una cosa diferente.Santiago 2:19 “Tú crees que Dios es uno; bien haces. También los demonios creen y tiemblan.”¿Qué es creerle a Dios? Creerle a Dios es confiar en Él, en su Palabra, en sus promesas. Algo difícilpara el ser humano es creer en lo que no se puede ver, en lo que no se puede tocar, en lo que notenemos enfrente de nosotros.(Mencionar tema y hablar de la imagen: miedo, confianza, seguridad, seguridad)A diario estamos expuestos a situaciones incómodas que nos desalientan y nos llenan de temor, ypreocupación, pero allí en medio de lo que está aconteciendo en nuestras vidas debemosagarrarnos del evangelio y avanzar creyéndole a Dios.Pero cuando la situación adversa viene una vez, y otra vez más y nuevamente nos golpea sinavisar, quizás nuestra reacción no sea la misma aunque ya hayamos escuchado el mensaje de Diosen más de una ocasión…Cuántas veces venimos escuchando la Palabra de Dios y en el momento decreerle a Él, se nos olvida lo escuchado. Nuestra humanidad a flor de piel.La palabra de Dios nos enseña mediante este pasaje de 1 Reyes 17 uno de los escenarios dondeDios se manifestó en gran manera usando al profeta Elías. Quien no dudó en ningún momento enobedecer el mandato de Dios.En aquellos tiempos Israel había sido desmoralizada ya que sus antiguos reyes llevaron al puebloa la idolatría, ya estaban rindiendo cultos a dioses paganos como Baal, por lo que no había ningúnsacerdote íntegro que llevara la Palabra de Dios al pueblo, por esto fue Elías elegido por Dios asícomo a otros hombres.Elías como sacerdote de Dios vivía en Fe y hacía como Él le ordenaba. Luego de haber traído laprofecía de la sequía al rey Acab 1.estuvo escondido en el arroyo de Querit y al cabo de unos días2.por ordenanza de Dios partió a Sarepta a encontrarse allí con una viuda y 3.un milagro.***El Señor traía a mi corazón el otro día una Palabra que primero fue para mi y luego meencomendó se la impartiera a alguien de aquí…llegó en un momento de adoración.Y hoy se la comparto a todos: “Si tu problema tiene un nombre, el Dios que servimos tambiéntiene nombre: Yahweh, Rapha, Elohim, Shaddai, Jireh, Adonai, El Roi.***Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Pharma industry tensions rise as Trump tariffs miss sector for now. FDA's interim CBER head appointed after key resignation. Xaira Therapeutics hires top AI academic. Novavax's COVID-19 shot review deadline missed by FDA. Trilink offers guide RNA for CRISPR workflow. Biotech sector sees investment surge. Beigene scraps candidate, Sarepta's gene therapy on hold in Europe. Biopharma professionals work long hours.In other news, there are safety concerns in Duchenne treatment. Democrats challenge Trump health cuts. And there are job opportunities in the biopharma industry.

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Zoll-Angst bei Pharma & Autos. Behörden-Angst bei Moderna, BioNTech, Sarepta & Sartorius. Giga-IPO bei Newsmax. Deals bei: Aston Martin, AMD, Globalfoundries, United Microelectronics, Rocket Companies, Mr. Cooper & Fortnox. Die Lieblingsaktie von Bill Gates. Eine Automatisierungswette. Halb so viel Volatilität wie die Börse. Das ist Waste Management (WKN: 893579). Tom Tailor, die Wolverhampton Wanderers und der Erfinder des Kinderwagens haben eins gemeinsam: Sie gehören Fosun (WKN: A0MVLL). Diesen Podcast vom 01.04.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

On this week's episode, Sam Fazeli, Eric Schmidt, and Brian Skorney are joined by Roivant's Matthew Gline to discuss data, deals and the latest policy updates. The episode kicks off with concerns over potential U.S. Department of Health and Human Services (HHS) funding cuts for domestic HIV programs, with the group analyzing the impact on companies like Gilead and GSK, whose HIV prevention drugs have driven significant investor enthusiasm. They then discuss the uncertainty surrounding the new administration's commitment to public health initiates, considering Robert F. Kennedy Jr.'s appointment as HHS Secretary and his past controversial views on vaccines and HIV prevention. The conversation then shifts to data, including positive results from Immunovant and Roivant's Phase 3 study of batoclimab for myasthenia gravis. The group also examines the surprising absence of short sellers engaging with Roivant post-data release, highlighting shifts in biotech trading strategies. In the muscular dystrophy space, new exon-skipping therapies from Avidity and Dyne show unprecedented dystrophin restoration, suggesting potential functional benefits. However, the tragic death of a patient treated with Sarepta's gene therapy, Elevidys, reignites concerns about accelerated approvals and the FDA's risk-benefit calculus in rare disease research. On the deal-making front, AstraZeneca's $425M acquisition of stealth-mode cell therapy startup EsoBiotec and Sanofi's $600M deal with Dren Bio underscore biotech's valuation disconnect, where early-stage private assets command premium prices while public biotechs struggle. The episode closes with insights into Alnylam's broad label win for Amvuttra in ATTR cardiomyopathy and AstraZeneca's $2.5B investment in biotech agreements and manufacturing in China, reflecting its long-term strategic vision despite ongoing geopolitical tensions. *This episode aired on March 21, 2025

President Donald Trump doubled down on tariff threats targeting pharma, saying additional levies on pharmaceuticals will come “at some point,” per CNBC. Meanwhile, Johnson & Johnson became the latest big pharma to respond to Trump's warning of potential tariffs if companies don't reshore their manufacturing, announcing a massive $55 billion U.S. manufacturing and R&D investment. Not all companies are on board, however: AstraZeneca is looking eastward, pumping $2.5 billion into a new research facility in Beijing.    Also on the policy front, Trump nominated acting CDC director Susan Monarez for the top job after pulling his first nominee, Dave Weldon, days before his senate hearing was expected to begin. If confirmed, Monarez would be the first CDC director since 1953 to not have a medical degree; she holds a Ph.D. in microbiology and immunology from the University of Wisconsin.   In weight loss news, Novo Nordisk is paying China-based United Laboratories $200 million upfront to license a triple agonist of the GLP-1, GIP and glucagon receptors that could one day compete with Eli Lilly's retatrutide. And BioSpace examines the next great challenge for GLP-1s: oral formulation manufacturing.    Two more therapeutic spaces in focus last week are Duchenne muscular dystrophy and spinal muscular atrophy, where companies including Dyne Therapeutics, REGENXBIO and Novartis presented new data on their respective candidates. And the Duchenne community continued to react to news of the death of a patient taking Sarepta's approved gene therapy Elevidys.  In cardiovascular news, Alnylam won a much-anticipated approval for Amvuttra as the first RNAi silencer for transthyretin amyloid cardiomyopathy, setting up a three-way race with Pfizer's tafamidis—marketed as Vyndaqel and Vyndama—and BridgeBio's Attruby. Next up is Milestone Therapeutics' CARDAMYST in paroxysmal supraventricular tachycardia, which has a PDUFA date of March 27.   Finally, the saga of Cassava Sciences' Alzheimer's hopeful simufilam is over, as the company announced it has ended development of the controversial candidate.   

Meditación del Evangelio según San Lucas 4, 24-30 por el biblista P. Norberto Padilla, misionero claretiano.Lunes 24/mar/2025, Jesús, al igual que Elías y Eliseo, no fue enviado solo a los judíos.Canción: Jesucristo Mi Señor (2025), de Kairy Marquez----------Lectura del santo evangelio según san Lucas 4, 24-30En aquel tiempo, dijo Jesús al pueblo en la sinagoga de Nazaret: "Les aseguro que ningún profeta es bien mirado en su tierra. Les garantizo que en Israel había muchas viudas en tiempos de Elías, cuando estuvo cerrado el cielo tres años y seis meses, y hubo una gran hambre en todo el país; sin embargo, a ninguna de ellas fue enviado Elías, más que a una viuda de Sarepta, en el territorio de Sidón. Y muchos leprosos había en Israel en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado, más que Naamán, el sirio." Al oír esto, todos en la sinagoga se pusieron furiosos y, levantándose, lo empujaron fuera del pueblo hasta un barranco del monte en donde se alzaba su pueblo, con intención de despeñarlo. Pero Jesús se abrió paso entre ellos y se alejaba.Palabra del Señor... Gloria a ti, Señor Jesús#SoyClaretiano #Evangelio #MisionerosClaretianos #CMFAntillasIntro: Lámpara Es Tu Palabra, de Ain Karem

+ Evangelio de nuestro Señor Jesucristo según san Lucas 4, 24-30 Cuando Jesús llegó a Nazaret, dijo a la multitud en la sinagoga: «Les aseguro que ningún profeta es bien recibido en su tierra. Yo les aseguro que había muchas viudas en Israel en el tiempo de Elías, cuando durante tres años y seis meses no hubo lluvia del cielo y el hambre azotó a todo el país. Sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda de Sarepta, en el país de Sidón. También había muchos leprosos en Israel, en el tiempo del profeta Eliseo, pero ninguno de ellos fue curado, sino Naamán, el sirio.» Al oír estas palabras, todos los que estaban en la sinagoga se enfurecieron y, levantándose, lo empujaron fuera de la ciudad, hasta un lugar escarpado de la colina sobre la que se levantaba la ciudad, con intención de despeñarlo. Pero Jesús, pasando en medio de ellos, continuó su camino. Palabra del Señor.

Lc 4,24-30.Cuando Jesús llegó a Nazaret, dijo a la multitud en la sinagoga: "Les aseguro que ningún profeta es bien recibido en su tierra.Yo les aseguro que había muchas viudas en Israel en el tiempo de Elías, cuando durante tres años y seis meses no hubo lluvia del cielo y el hambre azotó a todo el país.Sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda de Sarepta, en el país de Sidón.También había muchos leprosos en Israel, en el tiempo del profeta Eliseo, pero ninguno de ellos fue curado, sino Naamán, el sirio".Al oír estas palabras, todos los que estaban en la sinagoga se enfurecierony, levantándose, lo empujaron fuera de la ciudad, hasta un lugar escarpado de la colina sobre la que se levantaba la ciudad, con intención de despeñarlo.Pero Jesús, pasando en medio de ellos, continuó su camino.

En aquel tiempo, Jesús llegó a Nazaret, entró a la sinagoga y dijo al pueblo: “Yo les aseguro que nadie es profeta en su tierra. Había ciertamente en Israel muchas viudas en los tiempos de Elías, cuando faltó la lluvia durante tres años y medio, y hubo un hambre terrible en todo el país; sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda que vivía en Sarepta, ciudad de Sidón. Había muchos leprosos en Israel, en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado, sino Naamán, que era de Siria”.Al oír esto, todos los que estaban en la sinagoga se llenaron de ira, y levantándose, lo sacaron de la ciudad y lo llevaron hasta una saliente del monte, sobre el que estaba construida la ciudad, para despeñarlo. Pero él, pasando por en medio de ellos, se alejó de allí.

Lucas 4, 24-30: En aquel tiempo, Jesús llegó a Nazaret, entró a la sinagoga y dijo al pueblo: “Yo les aseguro que nadie es profeta en su tierra. Había ciertamente en Israel muchas viudas en los tiempos de Elías, cuando faltó la lluvia durante tres años y medio, y hubo un hambre terrible en todo el país; sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda que vivía en Sarepta, ciudad de Sidón. Había muchos leprosos en Israel, en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado, sino Naamán, que era de Siria”.Al oír esto, todos los que estaban en la sinagoga se llenaron de ira, y levantándose, lo sacaron de la ciudad y lo llevaron hasta una saliente del monte, sobre el que estaba construida la ciudad, para despeñarlo. Pero él, pasando por en medio de ellos, se alejó de allí.

Evangelio según San Lucas 4,24-30.Cuando Jesús llegó a Nazaret, dijo a la multitud en la sinagoga: "Les aseguro que ningún profeta es bien recibido en su tierra.Yo les aseguro que había muchas viudas en Israel en el tiempo de Elías, cuando durante tres años y seis meses no hubo lluvia del cielo y el hambre azotó a todo el país.Sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda de Sarepta, en el país de Sidón.También había muchos leprosos en Israel, en el tiempo del profeta Eliseo, pero ninguno de ellos fue curado, sino Naamán, el sirio".Al oír estas palabras, todos los que estaban en la sinagoga se enfurecierony, levantándose, lo empujaron fuera de la ciudad, hasta un lugar escarpado de la colina sobre la que se levantaba la ciudad, con intención de despeñarlo.Pero Jesús, pasando en medio de ellos, continuó su camino.________________Además puedes escuchar el Evangelio diario en las siguientes plataformas:Spotify: https://open.spotify.com/show/2M0Ubx3Jh55B6W3b20c3GOApple podcast: https://podcasts.apple.com/us/podcast/evangelio-del-d%C3%ADa/id1590423907 Para más información puede consultar nuestro sitio: https://www.vozcatolica.com o escríbanos a info@vozcatolica.com .Si quiere colaborar con este Apostolado lo puede hacer dirigiéndose a: https://vozcatolica.com/ayudanos . Desde ya muchas gracias.

Adquiere el "LIBRO DE ORACIÓN. Mi día a día con Jesús" en https://sercreyente.com/libros. Con más de 400 páginas, más de 500 oraciones y decenas de ilustraciones. Ve el vídeo en https://youtu.be/_9Z40IqjHj8________________Lunes, 24 de marzo de 2025 (3ª Semana de Cuaresma)Evangelio del día y reflexión... ¡Deja que la Palabra del Señor transforme tu vida! Texto íntegro del Evangelio y de la Reflexión (PDF): https://sercreyente.com/ningun-profeta-es-aceptado-en-su-pueblo/[Lucas 4, 24-30] Habiendo llegado Jesús a Nazaret, le dijo al pueblo en la sinagoga: «En verdad os digo que ningún profeta es aceptado en su pueblo. Puedo aseguraros que en Israel había muchas viudas en los días de Elías, cuando estuvo cerrado el cielo tres años y seis meses y hubo una gran hambre en todo el país; sin embargo, a ninguna de ellas fue enviado Elías sino a una viuda de Sarepta, en el territorio de Sidón. Y muchos leprosos había en Israel en tiempos del profeta Eliseo, sin embargo, ninguno de ellos fue curado sino Naamán, el sirio». Al oír esto, todos en la sinagoga se pusieron furiosos y, levantándose, lo echaron fuera del pueblo y lo llevaron hasta un precipicio del monte sobre el que estaba edificado su pueblo, con intención de despeñarlo. Pero Jesús se abrió paso entre ellos y seguía su camino.________________Descárgate la app de SerCreyente en https://sercreyente.com/app/¿Conoces nuestra Oración Online? Más información en: https://sercreyente.com/oracion¿Quieres recibir cada día el Evangelio en tu whatsapp? Alta en: www.sercreyente.com/whatsappTambién puedes hacer tu donativo en https://sercreyente.com/ayudanos/Contacto: info@sercreyente.com

+ Del Evangelio según san Lucas +En aquel tiempo, Jesús llegó a Nazaret, entró a la sinagoga y dijo al pueblo: «Yo les aseguro que nadie es profeta en su tierra. Había ciertamente en Israel muchas viudas en los tiempos de Elías, cuando faltó la lluvia durante tres años y medio, y hubo un hambre terrible en todo el país; sin embargo, a ninguna de ellas fue enviado Elías, sino a una viuda que vivía en Sarepta, ciudad de Sidón. Había muchos leprosos en Israel, en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado, sino Naamán, que era de Siria».Al oír esto, todos los que estaban en la sinagoga se llenaron de ira, y levantándose, lo sacaron de la ciudad y lo llevaron hasta una barranca del monte, sobre el que estaba construida la ciudad, para despeñarlo. Pero él, pasando por en medio de ellos, se alejó de allí.Palabra del Señor.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Sarepta's DMD gene therapy patient dies, causing a 22% drop in shares.Sarepta experienced a significant setback as a patient participating in their DMD gene therapy trial tragically passed away, leading to a 22% decrease in their shares.## Arbor raises $73.5 million for gene editing research.Arbor successfully secured $73.5 million in funding to further their research in gene editing, showcasing the growing interest and investment in this innovative field.## Opko and Entera collaborate on oral GLP-1/glucagon drug development.Opko and Entera have joined forces to collaborate on the development of an oral GLP-1/glucagon drug, combining their expertise to potentially revolutionize treatment options for patients.## Mirador aims to be a leading I&I breakthrough by 2030.Mirador has set ambitious goals to become a leading breakthrough in the field of inflammation and immunology by the year 2030, highlighting their commitment to advancing healthcare solutions.## Sino Biological offers reagents for 2025-2026 influenza vaccine strains.Sino Biological is providing reagents for the upcoming 2025-2026 influenza vaccine strains, contributing to the global efforts to combat infectious diseases and protect public health.## AstraZeneca invests $1.35 billion in subcutaneous cancer drugs with Alteogen alliance.AstraZeneca has made a substantial investment of $1.35 billion in subcutaneous cancer drugs through a strategic alliance with Alteogen, signaling their dedication to advancing oncology treatments.## DYNE's Duchenne exon skipping oligomer shows promising clinical effect.DYNE's Duchenne exon skipping oligomer has demonstrated promising clinical effects, offering hope for patients with this debilitating genetic disorder and potentially paving the way for new treatment options.Thank you for tuning in to Pharma and Biotech daily, where we bring you the latest updates and developments shaping the pharmaceutical and biotechnology industries. Stay informed and stay ahead in the world of healthcare innovation.

A patient with Duchenne muscular dystrophy taking Sarepta's gene therapy Elevidys has died of acute liver failure, possibly related to a recent viral infection. Sarepta, which said it will update Elevidys' label to reflect the new safety signal, saw its shares drop 22% on the news but analysts still seem positive on the drug, as treatment options for Duchenne remain limited.Meanwhile, both AstraZeneca and Taiho Pharmaceuticals announced acquisitions worth up to $1 billion or more in two sizzling therapeutic spaces, cell therapy and antibody-drug conjugates, respectively.Despite canceling a vaccine advisory committee late last month, the FDA on Thursday selected flu strains to be targeted in the upcoming 2025-2026 flu season. And at another federal agency, the Centers for Disease Control and Prevention, employees will have to wait a bit longer to see who will take the helm under Donald Trump, as the president's nominee, Dave Weldon, was pulled hours before he was set to appear before a Senate committee on Thursday. Like HHS Secretary Robert F. Kennedy Jr., Weldon has expressed anti-vaccine views in the past, particularly his continued suggestion of the link between vaccines and autism. Guggenheim Partners called the move to revoke Weldon's nomination “a positive sign for reigning in vaccine criticism.”In the weight loss arena, BioSpace takes deep dives into the tendency for biopharma to develop fast-followers, or me-too drugs—following a pattern seen with PD-1 checkpoint inhibitors after the approvals of Merck's Keytruda and Bristol Myers Squibb's Opdivo. One key difference between these two markets, however, is that when it comes to GLP-1s for weight loss, patients are not staying on these medicines. Drug developers are trying several approaches to improve treatment persistence, including titration, combinations and even secondary drugs that address side effects. They're also making other moves to differentiate themselves, including focusing on overall health outcomes—in areas like cardiovascular, sleep apnea and kidney disease.Following on BioSpace's coverage of the major patent cliffs that many Big Pharma companies are facing in coming years, we also take a look back at some of the companies that have already weathered such loss of exclusivity. It's rarely a straightforward story of sales crashing off patent, as companies take various tacks to extend their blockbuster sales.Finally, the cardiovascular space is expecting some movement this week. First, Alnylam is anticipating a decision on its RNAi silencer Amvuttra in ATTR-CM. An approval—which is widely expected—would make three companies on the market in this rapidly expanding space after Pfizer's tafamidis was approved in May of 2019, and BridgeBio's Attruby got the greenlight in November last year. And second, Milestone Pharmaceutical has a PDUFA coming up for etripamil in paroxysmal supraventricular tachycardia.

1 Reyes 17;8-248 Vino luego a él palabra de Jehová, diciendo: 9 Levántate, vete a Sarepta de Sidón, y mora allí; he aquí yo he dado orden allí a una mujer viuda que te sustente. 10 Entonces él se levantó y se fue a Sarepta. Y cuando llegó a la puerta de la ciudad, he aquí una mujer viuda que estaba allí recogiendo leña; y él la llamó, y le dijo: Te ruego que me traigas un poco de agua en un vaso, para que beba. 11 Y yendo ella para traérsela, él la volvió a llamar, y le dijo: Te ruego que me traigas también un bocado de pan en tu mano. 12 Y ella respondió: Vive Jehová tu Dios, que no tengo pan cocido; solamente un puñado de harina tengo en la tinaja, y un poco de aceite en una vasija; y ahora recogía dos leños, para entrar y prepararlo para mí y para mi hijo, para que lo comamos, y nos dejemos morir. 13 Elías le dijo: No tengas temor; ve, haz como has dicho; pero hazme a mí primero de ello una pequeña torta cocida debajo de la ceniza, y tráemela; y después harás para ti y para tu hijo. 14 Porque Jehová Dios de Israel ha dicho así: La harina de la tinaja no escaseará, ni el aceite de la vasija disminuirá, hasta el día en que Jehová haga llover sobre la faz de la tierra. 15 Entonces ella fue e hizo como le dijo Elías; y comió él, y ella, y su casa, muchos días. 16 Y la harina de la tinaja no escaseó, ni el aceite de la vasija menguó, conforme a la palabra que Jehová había dicho por Elías.17 Después de estas cosas aconteció que cayó enfermo el hijo del ama de la casa; y la enfermedad fue tan grave que no quedó en él aliento. 18 Y ella dijo a Elías: ¿Qué tengo yo contigo, varón de Dios? ¿Has venido a mí para traer a memoria mis iniquidades, y para hacer morir a mi hijo? 19 Él le dijo: Dame acá tu hijo. Entonces él lo tomó de su regazo, y lo llevó al aposento donde él estaba, y lo puso sobre su cama. 20 Y clamando a Jehová, dijo: Jehová Dios mío, ¿aun a la viuda en cuya casa estoy hospedado has afligido, haciéndole morir su hijo? 21 Y se tendió sobre el niño tres veces, y clamó a Jehová y dijo: Jehová Dios mío, te ruego que hagas volver el alma de este niño a él. 22 Y Jehová oyó la voz de Elías, y el alma del niño volvió a él, y revivió. 23 Tomando luego Elías al niño, lo trajo del aposento a la casa, y lo dio a su madre, y le dijo Elías: Mira, tu hijo vive. 24 Entonces la mujer dijo a Elías: Ahora conozco que tú eres varón de Dios, y que la palabra de Jehová es verdad en tu boca.-------------------Creemos en el poder de la generosidad y en el impacto positivo que podemos tener en la vida de los demás. Tu apoyo a través de donaciones desempeña un papel vital en nuestra misión de extender el amor de Cristo y dar ayuda a quien más lo necesitan.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://iglesiaguerrero.org/⁠⁠⁠

A partir da história da viúva de Sarepta, vamos refletir sobre esperança e necessidades.

On this episode, Daphne Zohar, John Maraganore, Josh Schimmer, Eric Schmidt and Sam Fazeli are joined by Endpoints' Zach Brennan for a discussion on the election results and what we can expect with a Trump administration, including the negatives/risks for the biotech industry as well as the positives and potential opportunities. The hosts also cover other news from the week including Moderna's Q3 earnings and the company's CEO Bancel stepping down as sales chief, as well as BioNTech's Q3 earnings and the potential softening of vaccine pricing. The group recapped the ASH conference and readouts including Arcellx's early data and related stock movement. The discussion turns to ObesityWeek highlights including data from AstraZeneca, Vertex, Zealand and Novo Nordisk. Other topics covered this week include Sarepta's SRP-5051 discontinuation, the death of gene editing and the impact to the fledgling field. This episode aired on November 8, 2024. 

On this week's episode, Brad Loncar, Chris Garabedian, Eric Schmidt, Paul Matteis and Sam Fazeli kick off with an open mic session on the potential impact of the RFK Jr. hearings and the Trump administration's policies on the biotech industry. The conversation turns to a “unicorn day” with IPOs for Metsara, Maze, Odyssey and Sionna Therapeutics. The group also discusses the approval of Vertex's journavx and the potential for it to be a blockbuster drug. Akero, Sarepta and Cargo also announced data this week and the hosts summarized the market reactions. Other topics covered include Merck's buyback announcement and potential impact on M&A activity, Takeda's CEO, Christophe Weber, steps down, Curie Bio's new fund, and more. This episode aired on January 31, 2025.

El pastor Moisés nos habla del amor que nos libera de la opresión de la crisis. Se basa en Lucas 4 y las historias de la viuda de Sarepta de Sidón y de Naamán el general sirio. Jesús nos muestra como Dios sanó y bendijo a los opresores de Israel y nos lleva a amar con el amor del Padre. - PRÓXIMOS PASOS  ¿Quieres dar el próximo paso? ¡Queremos ayudar! Envía un mensaje de texto con SIGUIENTE al 909-281-7797 o visítanos en sunrisechurch.org/nextsteps  - DAR A LA IGLESIA SUNRISE Imagina lo que Dios puede hacer cuando confiamos en Él para dar. Comienza a donar hoy en sunrisechurch.org/give  - SÍGUENOS EN LAS REDES SOCIALES:  Facebook: https://www.facebook.com/SunriseChurchCA  Instagram: https://www.instagram.com/sunrisechurchca  Youtube: https://www.youtube.com/SunriseChurch 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly projects a revenue miss for 2024 due to lower-than-anticipated sales of glp-1 blockbusters Mounjaro and Zepbound, causing their shares to drop by as much as 8%. Despite pressure to make a deal, Biogen executives refuse to do so out of desperation. The JPM25 conference featured presentations from Roche, Amgen, Merck, Lilly, and Biogen detailing their growth strategies. Keros fully terminates a mid-stage study on pulmonary arterial hypertension, potentially facing challenges ahead. AGC Biologics offers scale-down data for gene of interest candidates to accelerate timelines. Other news includes questions about accelerated approval for Biogen and Sarepta drugs, lessons learned from Neuropsych's stumbles, and increased drug prices by pharmacy benefit managers. Additionally, Lykos loses board directors after an FDA rejection, while biopharma deals start flowing at JPM25.Biogen executives, despite investor and analyst pressure, are not desperate to make a deal at JPM25. The biopharma industry saw a flood of deals at the event, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Seaport is learning from Neuropsych's mistakes amidst renewed interest in the field. The top VC raises in biotech for 2024 were highlighted, showing a significant increase in funding for the industry. J&J made a major neuro play with a $14.6 billion buyout, while Biogen submitted an offer to buy partner Sage. Overall, the industry sentiment has been reinvigorated by the flurry of deals at JPM25.

The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. Johnson & Johnson made the biggest splash, acquiring neurology leader Intra-Cellular Therapies for $14.6 billion, while GSK picked up precision therapy specialist IDRx for $1B upfront and Eli Lilly laid down up to $2.5 billion for Scorpion's PI3Kα inhibitor program. Meanwhile, the immunology and inflammation space continues to fire on all cylinders as Gilead invests up to $1.7 billion for LEO Pharma's preclinical oral small molecule STAT6 program. And those are only the deals accepted by both parties. Prior to the conference, Biogen offered to acquire its struggling neuro partner Sage Therapeutics for around $469M. The proposal follows a catastrophic run for Sage, which has seen its shares fall more than 90% in the past two years. 2024 sales and earnings forecasts have also generated attention this week, with Sarepta reporting that Duchenne muscular dystrophy gene therapy Elevidys beat analysts' expectations in the fourth quarter, and Eli Lilly projecting a full-year revenue miss driven largely by lower-than-expected sales of GLP-1 blockbusters Zepbound and Mounjaro. As expected, obesity has been a hot topic at JPM, with Pfizer CEO Albert Bourla announcing that his company is going “all in” in the space. This follows new FDA guidance revealed last week recommending a minimum weight loss threshold for drug developers. Among the many companies taking notice is newcomer Verdiva Bio, which launched last week with more than $410 million in opening funds. Also debuting last week was Kardigan, which raised $300 million to tackle heart disease. Kadigan joins a resurgent cardiovascular space, where several companies—including those developing gene therapies—are targeting myriad diseases. Finally, BioSpace senior editor Annalee Armstrong caught up with Daphne Zohar, CEO of BioSpace NextGen 2025 company Seaport Therapeutics Daphne Zohar, who offered her thoughts on the current state of the neuropsychiatric space.

Meditación del Evangelio según San Lucas 4, 16-30 por el biblista P. Norberto Padilla, misionero claretiano. Viernes 10/ene/2025, Lámpara para mis pasos - Hoy se ha cumplido esta Escritura. Canción: Espíritu (2020), de Jesús Cabello ---------- Lectura del santo evangelio según san Lucas 4, 16-30 En aquel tiempo, fue Jesús a Nazaret, donde se había criado. Entró en la sinagoga, como era su costumbre los sábados, y se puso en pie para hacer la lectura. Le entregaron el libro del profeta Isaías y, desarrollándolo, encontró el pasaje donde estaba escrito: "El Espíritu del Señor está sobre mí, porque él me ha ungido. Me ha enviado para dar la buena noticia a los pobres, para anunciar a los cautivos la libertad, y a los ciegos la vista; para dar libertad a los oprimidos, para anunciar el año de gracia del Señor." Y, enrollando el libro, lo devolvió al que le ayudaba y se sentó. Toda la sinagoga tenía los ojos fijos en él. Y él se puso a decirles: "Hoy se cumple esta Escritura que acaban de oír." Y todos le expresaban su aprobación y se admiraban de las palabras de gracia que salían de sus labios. Y decían: "¿No es este el hijo de José?" Y Jesús les dijo: "Sin duda me recitarán aquel refrán: 'Médico, cúrate a ti mismo, haz también aquí en tu tierra, lo que hemos oido que haz hecho en Cafarnaún'". Y añadió: "Les aseguro que ningún profeta es bien mirado en su tierra. Les garantizo que en Israel habían muchas viudas en tiempos de Elías, cuando estuvo cerrado el cielo tres años y seis meses, y hubo una gran hambre en todo el país. Sin embargo a ninguna de ellas fue enviado Elías, mas que a una viuda de Sarepta en el territorio de Sidón. Y muchos leprosos había en Israel en tiempos del profeta Eliseo; sin embargo, ninguno de ellos fue curado, mas que Naamán, el Sirio". Al oír esto, todos en la sinagoga se pusieron furiosos y, levantándose lo empujaron fuera del pueblo, hasta un barranco del monte donde se alzaba su pueblo, con intención de despeñarlo. Pero Jesús se abrió paso entre ellos y se alejaba. Palabra del Señor... Gloria a ti, Señor Jesús #SoyClaretiano #Evangelio #MisionerosClaretianos #CMFAntillas Intro: Lámpara Es Tu Palabra, de Ain Karem

====================================================SUSCRIBETEhttps://www.e.com/channel/UCNpffyr-7_zP1x1lS89ByaQ?sub_confirmation=1=======================================================================CONOZCO Y CUIDO MI CUERPODevoción Matutina Para Pequeños 2024Narrado por: Ministerio JAE AsturiasDesde: Gijón, Asturias, España===================|| www.drministries.org ||===================15 DE DICIEMBREUN PROFETA SEDIENTOVersículo: «Por favor, tráeme en un vaso un poco de agua para beber» 1 Reyes 17: 10DIOS ENVIÓ AL PROFETA ELÍAS a anunciar al rey Acab que no llovería por mucho tiempo porque el pueblo de Israel se había olvidado de él. Efectivamente, la sequía llegó y el profeta tuvo que esconderse en el arroyo de Querit de la furia del rey, que se encontraba desesperado porque no había agua para los animales y cultivos, así como para las personas.Dios le proveyó comida a Elías a través de los cuervos y agua del arroyo. Pero pronto, este se secó y sin agua para tomar, el profeta no viviría. Por tal motivo, Dios lo envió a Sarepta. Cuando llegó al lugar indicado, encontró una viuda recogiendo leña. Elías le pidió agua y comida, pues tenía mu cha sed y hambre. La viuda compartió con Elías lo que tenía y Dios también cuidó de ella y de su hijo.Actividad: Investiga con mami los daños que causa una sequía.Oración: Querido Padre, gracias porque provees agua para mí. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Exkivity have raised concerns about the risks of this pathway. Despite some high-profile failures, the program has a strong track record, with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like Sarepta's Elevidys have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next.AbbVie's Tavapadon showed improvement in motor and daily living complications in a Phase III trial, following the failure of another key cerevel asset, Emraclidine. Relmada Therapeutics is considering strategic alternatives, including a potential sale, after halting two Phase III trials for a major depressive disorder drug. Other news includes BioAge discontinuing a Phase II obesity study, Merck's promising anti-ROR1 ADC data for lymphoma treatment, and Novo and Catalent's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies, while evidence grows for the potential of GLP-1s in Alzheimer's disease.Recent studies have shown that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may have potential in treating Alzheimer's disease. Phase III results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP-1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lilly over Novo in a head-to-head study, FDA action alerts, and promising cancer therapies from companies like AstraZeneca and Merus. The FDA is also investigating the safety of Bluebird's gene therapy Skysona for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP-1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen toughen Tag für Tech, einen Kurssprung bei Iren und einen Dämpfer für Zinssenkungshoffnungen. Außerdem geht es um Intel, Parrot, eHang, AeroVironment, Northrop Grumman Corporation, Lockheed Martin, Kratos, Textron und Boeing, Elbit, Thales, SAAB, BAE Systems, Ambarella, Nvidia, AdvisorShares Drone Technology, ishares Global Aerospace &Defence (WKN: A3E1JS), Invesco Defense Innovation (WKN: A40J95), Rocket Lab, Leidos Holdings, Iris Energy, Arrowhead, Bitcoin, Sarepta, VW und Amundi MSCI USA Ex Mega Cap ETF (WKN: ETF222), Amundi MSCI USA Mega Cap UCITS ETF (WKN: ETF220) Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Trump has chosen Jay Bhattacharya from Stanford as the new head of the National Institutes of Health, adding to his controversial cabinet picks. Meanwhile, Eli Lilly is currently the best performing pharmaceutical stock of 2024. The newsletter will be taking a break for Thanksgiving and will return on December 2nd with more biopharma news. In other news, PTC has discontinued an ALS asset after a mid-stage failure, BridgeBio's ATTR-CM drug has been approved, Cassava's Alzheimer's drug has failed in Phase III, and Amgen's Maritide did not impress investors. Eli Lilly has seen a significant improvement in its share price this year, while other pharmaceutical companies have not been as fortunate. Additionally, there have been layoffs at Novartis, Recursion, and Kronos. Legal challenges over Lilly's GLP-1 shortages and Sarepta's investment in Arrowhead for RNA drugs are also highlighted.Eli Lilly leads the list of the biggest share movers in the pharmaceutical industry this year, with a significant improvement in its share price. However, other companies like Amgen have faced disappointments, with their weight loss drug Maritide falling short of investor expectations. Sage Therapeutics also suffered setbacks with the discontinuation of its lead candidate Dalzanemdor after clinical failures. Legal challenges over Lilly's GLP-1 shortages have highlighted the FDA's vulnerability post-Chevron deference. In other news, Roche acquires Poseida, Sarepta aims to diversify its pipeline with RNA drugs, and Trump's cabinet picks raise uncertainty in the biopharma environment. Novartis CEO promises more deals, while companies like Novartis, Recursion, and Kronos have announced layoffs. Subscribe for more relevant updates from BioSpace.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Amgen's weight loss drug Maritide fell short of expectations, with only a 20% weight loss reported, causing a drop in the company's shares. In other news, Sarepta made a significant commitment of up to $10 billion in a deal with Arrowhead to expand its pipeline with RNA drugs. Roche also made a strategic move by acquiring Poseida for up to $1.5 billion, but faced a setback with a Phase III failure for its TIGIT asset. Alector's Alzheimer's program suffered a setback with a failed Phase II trial, leading to a 17% layoff. Lilly encountered legal challenges related to GLP-1 shortages, while AstraZeneca celebrated success with its Truqap in a Phase III prostate cancer trial.These developments are reshaping the landscape of the biotech industry, offering new opportunities in roles such as manufacturing engineer, associate director of preclinical development, data analyst scientist, and executive director of marketing. Stay informed with more news and updates on Biospace's website.

Genethon, the non-profit gene therapy developer created by the patient association AFM-Telethon, began working with Sarepta Therapeutics in 2017 to develop a gene therapy for the rare neuromuscular condition Duchenne muscular dystrophy. Now that Sarepta has won approval for a separate gene therapy to treat the condition, Genethon is advancing development of its experimental gene therapy on its own. We spoke to Frederic Revah, CEO of Genethon, about Duchenne, the organization's efforts to complete clinical development of its gene therapy for the condition, and how it might commercialize the treatment.

P. Juan (Argentina)Las lecturas de este domingo nos ponen el ejemplo de dos mujeres viudas que dan a Dios lo que todo lo que tienen por la confianza que tienen en Él.[Ver Meditación Escrita] https://www.hablarconjesus.com/meditacion_escrita/menos-tienen-y-mas-dan-dios/

Send us a textEn ce 32e dimanche, Martine Kouadio-Gokra nous invite à réfléchir sur le sens profond de donner avec foi et confiance. À travers les exemples de la veuve de Sarepta et de la veuve de l'Évangile, Martine nous montre l'importance de donner de tout cœur, même dans la difficulté, en s'abandonnant totalement à Dieu.Ces femmes nous rappellent que la vraie richesse se trouve dans une foi qui se traduit par des actes de générosité. En ouvrant nos mains et notre cœur, nous permettons à Dieu de travailler en nous et de répondre à nos besoins.Rejoignez cette méditation pour découvrir comment vivre une foi qui donne sans crainte. Abonnez-vous, partagez vos réflexions en commentaire, et que cette parole vous inspire à une foi généreuse.

La Liturgia de este Domingo 32, Ordinario, nos invita a la generosidad basada no tanto en lo que tenemos cuanto en lo que somos y lo hace mostrándonos como modelos de generosidad admirable a dos viudas, la de Sarepta quien alimento al profeta Elias con lo único que tenía para sobrevivir ella y su hijito, un poco de harina y un poco de aceite. Y el otro ejemplo la viuda pobre que depositó en  la alcancía del Templo las dos únicas moneditas que tenía y sin darse cuenta que era observada por Jesús y puesta como ejemplo ante sus discípulos. El gran mensaje que resalta a la vista en las Lecturas de hoy es la grandeza y el valor de las pequeñas cosas y si aún carecemos de estas pequeñísimas cosas, podemos  todavía dar nuestro humilde servicio a cambio de nada, o sí, a cambio de la alegría de poder servir desinteresadamente . Y lo más consolador es saber que tenemos un Dios que observa con ternura las actitudes más allá de las apariencias, un Dios que mira sobre todo las intenciones que nos mueven a obrar en favor del necesitado. Dios no hace acepción de personas, ni se deja impresionar por los que quieren ocupar los primeros puestos, se fija más bien en aquellos que nadie se fija y por lo tanto nunca serán los primeros. Pero resulta que, con Dios gana el que siempre pierde, porque Dios colma nuestra esperanza de ser un día definitivamente  valorados y tenidos en cuenta como la viuda pobre del Evangelio de hoy.  Feliz semana realizando con amor las pequeñas cosas que nos hacen realmente felices.  Bendiciones, Hna. Maria Ruth  Radio Paulinas Boston

Has the fever broken for the high momentum stocks? Nvidia running out of steam this week, as some other high fliers also pull back. Is this just a bump in the road or the beginning of a summer slowdown? Plus Sarepta's big surge. The biotech company getting expanded approval from the FDA for its muscular dystrophy drug. What the CEO says is next for the company. Fast Money Disclaimer